Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of Personalized First-line Chemotherapy Choice for Patients With Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures (PACsign)

NCT05475366 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT05475366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05475366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of Personalized First-line Chemotherapy Choice for Patients With Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures (PACsign)
Lead sponsor
Institut Curie
Phase
Not applicable
Overall status
Active, not recruiting
Start date
December 12, 2022
Completion date
December 11, 2028
Enrollment
79 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, pancreatic ductal, prognosis